Pando Bioscience
Gen-AI Designed Enzymes for Pharmaceutical Innovation
What they do
Pharmaceutical companies need faster, cheaper ways to discover and optimize enzymes with the right performance properties for drug development and manufacturing.
An AI-driven enzyme engineering platform combining generative AI with ultra-high-throughput screening to design, test, and optimize tailored enzymes at dramatically higher speed and lower cost.
Pharmaceutical and biomanufacturing companies that require optimized enzymes for R&D and production processes.
Founders
Will Cao is the co-founder and CEO of Pando Bioscience. During her Ph.D., Will changed her major from engineering machines to engineering bacteria (yes, making genetic modifications to bacteria, so they can produce things that they can't before). She has published first-author papers in Cell and Nature Biotechnology. In her spare time, she is a personal trainer and a kayak and scuba diving enthusiast.
Company timeline
- Founded2022
- YC batchWinter 2023
- StatusActive
- Team size5 people
- LocationBoston, MA, USA
Similar startups
